期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 13, 期 5, 页码 515-524出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0071
关键词
-
类别
资金
- Eisai
- Bristol-Myers Squibb
- Genentech BioOncology
- Merck
- Novartis Oncology
- Novocure
- Boehringer Ingelheim Pharmaceuticals, Inc.
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据